Figure1: The picture depicted the spherical Structure of SARS-CoV-2, external components, and viral single stranded RNA.
Figure 2: the chart depicts the number of cases, deaths, and recoveries from the SARS-COV1 during the time of infection (November 2002 through July 2003).
Figure 3: the chart in the picture reveal the number of confirm cases in Yellow, deaths in Red and the recovered from the infectious depicted by Green color.
Figure 4: The chart expressing the number of confirmed cases of SARS-COVID19 around the world in Yellow, the level of deaths in the Red , and the Green column shows recovered number from the pandemic infectious disease, according to the day of preparing research.
Figure 5: In the left shown the approximate average fatality rate among SARS-COVID1 in Yellow with 10%, MERS in Red with 34% and the ongoing SARS-COVID 19 in Blue color with the average 5%.
Figure 6: From the charts that belongs to each infectious we also can conclude the comparison between then in the following table. it shows us an incredible result.
Figure 7: the most dangerous rate of deaths recorded in Iran and Iraq. fatality case rates in both countries are more than 4% Whereas The fatality case rates in other countries are less than 1%, notably Qatar recorded the lowest degree and located at the bottom of the level with the fatality case rate 0.1%.
Figure 8: according to the population number Qatar has the highest level of infection rate as shown by the Red column, and Iraq takes the lowest level of infection illustrated in green couln. Others like Bahrain with the rate of (0.018), Kuwait is 0.012, Oman in the level of (0.01), KSA record is 0.006, UAE at the rate of (0.005), and Iran (0.002) by the population number.
REFERENCES
1.Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. 2020. A novel Coronavirus emerging in China-key questions for impact assessment N Engl J Med 10.1056/NEJMp200092.1056/NEJMp20009299. doi:10
2. De Haan, C.A.; Rottier, P.J. Molecular interactions in the assembly of coronaviruses. Adv Virus Res. 2005, 64, 165-230, https://doi.org/10.1016/S0065-3527(05)64006-7.
3.Bárcena, M.; Oostergetel, G.T.; Bartelink, W.; Faas, F.G.A.; Verkleij, A.; Rottier, P.J.M.; Koster, A.J.;
Bosch, B.J. Cryo-electron tomography of mouse hepatitis virus: Insights into the structure of the
coronavirion. Proceedings of the National Academy of Sciences 2009, 106,
https://doi.org/10.1073/pnas.0805270106.
4.Roy, A.; Kucukural, A.; Zhang, Y. I-TASSER: a unified platform for automated protein structure and
function prediction. Nature Protocols 2010, 5, 725-738, https://doi.org/10.1038/nprot.2010.5.
5.Duquerroy, S.; Vigouroux, A.; Rottier, P.J.; Rey, F.A.; Bosch, B.J. Central ions and lateral
asparagine/glutamine zippers stabilize the post-fusion hairpin conformation of the SARS coronavirus spike glycoprotein. Virology 2005, 335, 276-285, https://doi.org/10.1016/j.virol.2005.02.022.
6.Monajjemi, M. Graphene/(h-BN)n/X-doped raphene as anode material in lithium ion batteries (X = Li, Be, B AND N). Macedonian Journal of Chemistry and Chemical Engineering 2017, 36, 101–118,
http://dx.doi.org/10.20450/mjcce.2017.1134.
7.Zhang, L.; Liu, Y. Potential interventions for novel coronavirus in China: A systematic review. Journal of
Medical Virology 2020, 92, 479-490, https://doi.org/10.1002/jmv.25707.
8.Sanders, J.M.; Monogue, M.L.; Jodlowski, T.Z.; Cutrell, J.B. Pharmacologic Treatments for Coronavirus
Disease 2019 (COVID-19): A Review. JAMA 2020, 323, 1824-1836,
https://doi.org/10.1001/jama.2020.6019.
9.Grein, J.; Ohmagari, N.; Shin, D.; Diaz, G.; Asperges, E.; Castagna, A.; Feldt, T.; Green, G.; Green, M.L.;
Lescure, F.-X.; Nicastri, E.; Oda, R.; Yo, K.; Quiros-Roldan, E.; Studemeister, A.; Redinski, J.; Ahmed, S.;
Bernett, J.; Chelliah, D.; Chen, D.; Chihara, S.; Cohen, S.H.; Cunningham, J.; D’Arminio Monforte, A.;
Ismail, S.; Kato, H.; Lapadula, G.; L’Her, E.; Maeno, T.; Majumder, S.; Massari, M.; Mora-Rillo, M.; Mutoh,
Y.; Nguyen, D.; Verweij, E.; Zoufaly, A.; Osinusi, A.O.; DeZure, A.; Zhao, Y.; Zhong, L.; Chokkalingam,
A.; Elboudwarej, E.; Telep, L.; Timbs, L.; Henne, I.; Sellers, S.; Cao, H.; Tan, S.K.; Winterbourne, L.; Desai,
P.; Mera, R.; Gaggar, A.; Myers, R.P.; Brainard, D.M.; Childs, R.; Flanigan, T. Compassionate Use of
Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine 2020.
10. Li, J.; Li, J.; Xie, X.; Cai, X.; Huang, J.; Tian, X.; Zhu, H. Game consumption and the 2019 novel coronavirus. The Lancet Infectious Diseases 2020, 20, 275-276, https://doi.org/10.1016/S1473-3099(20)30063-3.
11.Sun, P.; Qie, S.; Liu, Z.; Ren, J.; Li, K.; Xi, J. Clinical characteristics of hospitalized patients with SARS-
CoV-2 infection: A single arm meta-analysis. Journal of Medical Virology 2020, 92, 612-617, https://doi.org/10.1002/jmv.25735.
12.Poston, J.T.; Patel, B.K.; Davis, A.M. Management of Critically Ill Adults With COVID-19. JAMA 2020, 323, 1839-1841, https://doi.org/10.1001/jama.2020.4914
13.Lu H. 2020. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 10.5582/bst.2020.01020. doi: 10.5582/bst.2020.01020.
14.Pillaiyar T, Meenakshisundaram S, Manickam M. 2020. Recent discovery and development of inhibitors targeting coronaviruses. Drug Discov Today S1359- 6446(20)30041-6. doi: 10.1016/j.drudis.2020.01.015.
15.Ng OW, Tan YJ. 2017. Understanding bat SARS-like coronaviruses for the preparation of future corona virus outbreaks-Implications for coronavirus vaccine development. Hum VaccinImmunother 13(1):186-189. doi: 10.1080/21645515.2016.1228500.
16.Chen J. 2020. Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses. Microbes Infect S1286-4579(20)30026-5. doi:10.1016/j.micinf.2020.01.004.
17. WHO. 2020. World Health Organization. Coronavirus disease 2019 (COVID-19) situation report, Situation report – 33 (22ndFebruary 2020). Available online: https://www.who.int/docs/default-source/coronaviruse/situationreports/20200222-sitrep-33-covid-19.pdf (accessed on 25 February 2020).
18.Chen Y, Liu Q, Guo D. 2020. Emerging coronaviruses: genome structure, replication, and pathogenesis J Med Virol 10.1002/jmv.25681. doi:10.1002/jmv.25681.
19. Zhu N, Zhang D, Wang W, et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. doi:10.1056/NEJMoa2001017
20. US Food and Drug Administration. Investigational COVID-19 Convalescent plasma: emergency INDs. Updated April 3, 2020. Accessed
21. World Health Organization. Clinical management of severe acute respiratory infection when COVID-19 is suspected. Updated March 13, 2020. Accessed March 18, 2020. https://www.who. int/publications-detail/clinical-management-ofsevere-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected
22. Arabi YM, Mandourah Y, Al-Hameed F, et al; Saudi Critical Care Trial Group. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757-767. doi:10.1164/rccm.201706- 1172OC
23. Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocul Immunol Inflamm 2020: 1-5
24. Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoVda target for vaccine and therapeutic development. Nat Rev Microbiol 2009;7(3):226e36
25. ”UAE CORONAVIRUS (COVID-19) UPDATES”. UAE’s national emergency crisis and disaster management authority. Retrieved 15 April 2020.
26. Reynolds, Matt (4 March 2020). ”What is coronavirus and how close is it to becoming a pandemic?”. Wired UK. ISSN 1357-0978. Archived from the original on 5 March 2020. Retrieved 5 March 2020
27.World Federation Of Societies of Anaesthesiologists – Coronavirus”. www.wfsahq.org . Archived from the original on 12 March 2020. Retrieved 15 March 2020
28. ”Qatar reports 951 new confirmed cases, 114 new recovered cases of COVID-19”. www.iloveqatar.net. Retrieved 27 May 2020.